Safety and efficacy of chidamide for maintenance therapy after allogeneic hematopoietic stem cell transplantation in patients with T-ALL/T-LBL

内科学 维持疗法 医学 血液学 不利影响 移植 造血干细胞移植 肿瘤科 比例危险模型 入射(几何) 临床终点 前瞻性队列研究 外科 干细胞 毒性 累积发病率 造血 生存分析 多元分析 疾病 单变量分析
作者
Kuangfei Wang,Xiaojing Li,Xiaofan Li,Xiaohong Yuan,Xianling Chen,Xiaohui Lai,Nainong Li,Ping Chen
出处
期刊:Annals of Hematology [Springer Science+Business Media]
标识
DOI:10.1007/s00277-026-07016-x
摘要

Post-transplant relapse remains a primary obstacle to long-term survival in patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/T-LBL), underscoring the need for effective maintenance therapies. Although chidamide, a selective histone deacetylase inhibitor, has shown activity in T-cell malignancies, its role as post-transplant maintenance has been scarcely studied. To evaluate the efficacy and safety of chidamide as maintenance therapy in T-ALL/T-LBL patients after allogeneic hematopoietic stem cell transplantation (allo-HSCT). We retrospectively analyzed 75 T-ALL/T-LBL patients who underwent allo-HSCT (December 2019-January 2024). Thirty-eight patients received chidamide-based maintenance, and 37 served as controls (no maintenance or non-chidamide regimens). The primary endpoints were overall survival (OS) and progression-free survival (PFS); safety endpoints included graft-versus-host disease (GVHD) incidence and treatment-related adverse events. Chidamide maintenance was associated with significantly improved OS and PFS compared with the non-chidamide group (OS: p = 0.001; PFS: p = 0.006). Multivariate Cox regression identified chidamide maintenance (OS: p = 0.003; PFS: p = 0.006) and complete remission status before transplantation (OS: p = 0.013; PFS: p = 0.012) as independent favorable prognostic factors. Chidamide did not increase acute GVHD; chronic GVHD was numerically higher (26.32% vs. 13.51%) but mostly mild to moderate and manageable. Adverse events were primarily hematologic toxicity (bone marrow suppression) and gastrointestinal, generally manageable and rarely required treatment discontinuation. Chidamide maintenance after allo-HSCT significantly improves survival outcomes in T-ALL/T-LBL patients with an acceptable safety profile, while pre-transplant remission status further refines prognosis. Prospective studies are warranted to confirm these findings and optimize maintenance strategies in this setting.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
bowen完成签到,获得积分10
刚刚
刚刚
1秒前
lele发布了新的文献求助10
1秒前
111发布了新的文献求助10
1秒前
无花果应助简单的笑容采纳,获得10
1秒前
Lemon完成签到 ,获得积分10
3秒前
3秒前
辛勤的紫蓝完成签到 ,获得积分10
4秒前
科研通AI6.4应助石榴采纳,获得10
5秒前
lipppfff发布了新的文献求助10
5秒前
领导范儿应助靖哥哥采纳,获得10
5秒前
6秒前
ding应助zhuoai采纳,获得10
7秒前
NexusExplorer应助甲乙丙丁采纳,获得10
7秒前
Raymond发布了新的文献求助10
7秒前
7秒前
JamesPei应助chyen采纳,获得10
8秒前
Qiiii完成签到,获得积分10
9秒前
科研通AI2S应助热情果汁采纳,获得10
9秒前
脑洞疼应助论文2采纳,获得10
9秒前
11秒前
科科完成签到,获得积分10
12秒前
12秒前
13秒前
乐乐应助suannai采纳,获得10
13秒前
mix完成签到 ,获得积分10
13秒前
14秒前
柔弱凛完成签到,获得积分20
14秒前
15秒前
15秒前
明亮的嚣完成签到,获得积分10
16秒前
古古完成签到,获得积分10
16秒前
科研通AI6.4应助meng采纳,获得10
16秒前
17秒前
17秒前
18秒前
六六发布了新的文献求助10
18秒前
zhangxun完成签到,获得积分10
18秒前
高分求助中
Principles of Economics, 11th Edition 10000
Prescott's Microbiology: 2026 Release ISE 10000
University Physics with Modern Physics, 16th edition 10000
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Environmental Leverage in Times of Climate Crisis: Product Standards, Carbon Border Measures and Preferential Trade Agreements 1000
Interactions of Vowel Quality and Prosody in East Slavic 1000
Erwählung und Berufung bei Paulus: Bedeutung, Entwicklung und Funktion einer Vorstellung in ihrem frühjüdischen und griechisch-römischen Kontext 850
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7171894
求助须知:如何正确求助?哪些是违规求助? 8812836
关于积分的说明 18619135
捐赠科研通 6787453
什么是DOI,文献DOI怎么找? 3167751
关于科研通互助平台的介绍 2309591
邀请新用户注册赠送积分活动 2142397